TMEM212 Inhibitors
TMEM212, an ortholog of the human CROCC2 gene, plays a critical role in cellular processes, as evidenced by its expression in various tissues, including the central nervous system, dorsal root ganglion, embryo mesenchyme, and lung. Despite its importance, the precise function of TMEM212 is not fully elucidated, and further research is needed to uncover its specific molecular roles in cellular homeostasis and signal transduction. As a member of the transmembrane protein family, TMEM212 likely participates in intracellular signaling or membrane-related functions. The widespread expression across diverse tissues hints at its involvement in fundamental cellular processes, potentially influencing cell signaling, differentiation, or response to extracellular cues.
Inhibition of TMEM212 can be achieved through diverse mechanisms, involving the disruption of specific signaling pathways crucial for its function. Chemical inhibitors targeting PI3K/AKT and MAPK pathways directly impact TMEM212, suggesting its involvement in these cascades. Additionally, compounds affecting autophagy and lysosomal function indirectly influence TMEM212, indicating potential interactions with cellular turnover processes. The intricate regulatory network suggests that TMEM212 may be responsive to alterations in key cellular pathways, and its inhibition can be manipulated through diverse chemical interventions. The exploration of these inhibitors offers a window into understanding the complex interplay between TMEM212 and cellular processes, paving the way for further investigations into its molecular functions and potential roles in health and disease.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor affecting PI3K/AKT signaling. Directly inhibits TMEM212 by disrupting downstream signaling events crucial for its function. Altered PI3K/AKT signaling interferes with the expression or activity of TMEM212, leading to inhibition. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor affecting the MAPK pathway. Directly inhibits TMEM212 by disrupting MAPK signaling, crucial for its function. Altered MAPK signaling influences the expression or activity of TMEM212, leading to inhibition. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
V-ATPase inhibitor affecting lysosomal acidification. Indirectly inhibits TMEM212 by disrupting lysosomal function, impacting its turnover. Altered lysosomal activity may influence the expression or activity of TMEM212, leading to inhibition. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $94.00 $413.00 | 16 | |
EGFR inhibitor affecting receptor tyrosine kinase signaling. Directly inhibits TMEM212 by disrupting EGFR-mediated signaling events crucial for its function. Altered EGFR signaling interferes with the expression or activity of TMEM212, leading to inhibition. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Autophagy inhibitor affecting lysosomal function. Indirectly inhibits TMEM212 by disrupting autophagy, impacting its turnover. Altered autophagic activity may influence the expression or activity of TMEM212, leading to inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor affecting PI3K/AKT signaling. Directly inhibits TMEM212 by disrupting downstream signaling events crucial for its function. Altered PI3K/AKT signaling interferes with the expression or activity of TMEM212, leading to inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor affecting mTORC1 signaling. Indirectly inhibits TMEM212 by disrupting mTOR-related signaling events, impacting its turnover. Altered mTORC1 activity may influence the expression or activity of TMEM212, leading to inhibition. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Autophagy inhibitor affecting Beclin1 and VPS34 interaction. Indirectly inhibits TMEM212 by disrupting autophagy, impacting its turnover. Altered autophagic activity may influence the expression or activity of TMEM212, leading to inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor affecting the p38 MAPK signaling pathway. Directly inhibits TMEM212 by disrupting p38 MAPK signaling events crucial for its function. Altered p38 MAPK signaling interferes with the expression or activity of TMEM212, leading to inhibition. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
Autophagy inhibitor affecting PI3K class III. Indirectly inhibits TMEM212 by disrupting autophagy, impacting its turnover. Altered autophagic activity may influence the expression or activity of TMEM212, leading to inhibition. | ||||||